Trental
Phase 2Small molecule
Trental is one of 51 small molecule programs targeting Necrosis. It is currently in Phase 2.
2
Indications
4
Total Trials
0
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
57 competitors in Necrosis
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Integrilin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Zoloft
VViatris Specialty LLC
Approved
Botox
AbbVieApproved
Adenocard
AstellasPhase 3
Crestor
AstraZenecaPhase 3
Stelara
Johnson & JohnsonPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Angiomax
BBaxter Healthcare Corporation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Dialysis Patients1 trial
Pentoxifylline Administration in Hemodialysis Patients
Unknown status·—·Phase 1·NCT03800433·46 enrolled
MPA1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Trental. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- PProcessa Pharmaceuticals